Melior Pharmaceuticals
Mid-stage biopharmaceutical company developing a de-risked pipeline of clinical-stage drug candidates for metabolic and CNS disorders. Leverages an affiliate's proprietary in vivo phenotypic screening platform to identify new indications for compounds with prior clinical safety data, advances candidates through preclinical models and Phase 2 clinical studies, and pursues partnerships and licensing to advance development.
Industries
Nr. of Employees
small (1-50)
Melior Pharmaceuticals
860 Springdale Drive, Suite 500, Exton, PA 19341
Patents
Methods and formulations for modulating Lyn kinase activity and treating related disorders
US-12070461-B2
View DetailsMethods and formulations for modulating Lyn kinase activity and treating related disorders
US-11033548-B2
View Details
Methods and formulations for modulating Lyn kinase activity and treating related disorders
US-12070461-B2
View DetailsMethods and formulations for modulating Lyn kinase activity and treating related disorders
US-11033548-B2
View DetailsProducts
Tolimidone (clinical-stage lyn kinase activator)
Clinical-stage small molecule that selectively activates Lyn kinase to potentiate insulin signaling and modulate lipid biology; developed for Type 2 Diabetes and Nonalcoholic Steatohepatitis (NASH); completed Phase 2a and Phase 2b studies.
Mesocarb (dopamine reuptake inhibitor)
Well-characterized dopamine reuptake inhibitor in development for L-DOPA-induced dyskinesia in Parkinson's disease and for certain sleep disorders; previously marketed outside the U.S. with extensive historical safety exposure.
Tolimidone (clinical-stage lyn kinase activator)
Clinical-stage small molecule that selectively activates Lyn kinase to potentiate insulin signaling and modulate lipid biology; developed for Type 2 Diabetes and Nonalcoholic Steatohepatitis (NASH); completed Phase 2a and Phase 2b studies.
Mesocarb (dopamine reuptake inhibitor)
Well-characterized dopamine reuptake inhibitor in development for L-DOPA-induced dyskinesia in Parkinson's disease and for certain sleep disorders; previously marketed outside the U.S. with extensive historical safety exposure.
Services
Custom in vivo pharmacology experiments and discovery-stage screening provided to external pharmaceutical clients, including disease-model testing and efficacy assessments.
Custom in vivo pharmacology experiments and discovery-stage screening provided to external pharmaceutical clients, including disease-model testing and efficacy assessments.
Expertise Areas
- Drug repositioning / repurposing
- In vivo phenotypic screening
- Preclinical disease modeling (NASH, metabolic disease)
- Translational pharmacology
Key Technologies
- In vivo phenotypic screening
- Validated animal disease models (NASH and metabolic models)
- Translational biomarkers
- Mixed meal tolerance testing (MMTT)
News & Updates
Received IND clearance from the U.S. FDA for a COVID-19 therapeutic program.
Awarded a grant to support initiation of a COVID-19 clinical trial.
Announced positive Phase 2b clinical study results for tolimidone in Type 2 Diabetes.
Executed a license agreement for a Parkinson's disease candidate with a third party.
Received SBIR grant funding to study a drug candidate's mechanism of action.
Received IND clearance from the U.S. FDA for a COVID-19 therapeutic program.
Awarded a grant to support initiation of a COVID-19 clinical trial.
Announced positive Phase 2b clinical study results for tolimidone in Type 2 Diabetes.
Executed a license agreement for a Parkinson's disease candidate with a third party.
Received SBIR grant funding to study a drug candidate's mechanism of action.